Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?Alessandra Iurlo, Agostino Cortelezzi, Dario Consonni et al.|Oncotarget|2015Cited by 67
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter seriesAlessandra Iurlo, Michele Baccarani, Federica Sorà et al.|Annals of Hematology|2017Cited by 38
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Pier Mannuccio Mannucci, Alessandro Nobili et al.|Oncotarget|2016Cited by 35
Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patientsAlessandra Iurlo, Agostino Cortelezzi, Anna Ubertis et al.|European Journal of Internal Medicine|2013Cited by 34
Imatinib and ruxolitinib association: first experience in two patientsAlessandra Iurlo, Agostino Cortelezzi, Umberto Gianelli et al.|Haematologica|2014Cited by 29